Particle.news
Health ❯ Healthcare ❯ Patient Care
Support Systems Quality of Life Resource Allocation Alzheimer's Disease Treatment Alzheimer's Treatment Alzheimer's Treatment Options Lupus Treatment Quadriparesis Recovery High Blood Pressure Heart Disease Management Medication Adherence Cognitive Impairment Type 2 Diabetes Bladder Cancer Support Huntington's Disease Living with LAD-1 Inflammatory Bowel Disease Parkinson's Disease Management Memory Disorders Therapeutic Approaches Dialysis Treatment Support Services Huntington's Disease Support Heart Failure Treatment Access to Care Blood Cancer Huntington's Disease Treatment Patient Communication Interprofessional Collaboration Type 1 Diabetes Pediatric Care Hypertension Solutions Type 1 Diabetes Treatment Cystic Fibrosis Treatment Dementia Care Bronchial Asthma Innovative Therapies Epilepsy Syndromes Alzheimer's Disease Progression of Disease Parkinson's Disease Treatment Awareness and Education Alzheimer's Care Disease Management Programs Rheumatoid Arthritis Treatment Vaccination for Vulnerable Populations Kidney Disease Treatment Home Healthcare Vaccination Recommendations Long-term Medications Kidney Health Kidney Disease Heart Failure Non-Cystic Fibrosis Bronchiectasis Treatment GvHD Patient Population Multiple Sclerosis Treatment Injection Therapy Motor Fluctuations Cognitive Decline
The decision follows Phase 2 and 3 trials showing higher complete renal response with obinutuzumab versus standard therapy alone.
